Teva Generics CEO Quits

Source: TheStreet

Dec 07, 2016

Siggi Oli Olafsson is stepping down as president and CEO of Teva Pharmaceutical's global generic medicines group.

The decision comes less than two-and-a-half years following Olafsson's appointment, and has caused concern among investors. Teva has appointed the company's existing CEO and president of Teva Generics Europe, Dipankar Bhattacharjee, as Olafsson's successor.

Teva referred to Olafsson's exit -- will take effect at the end of the first quarter of 2017 -- as a "retirement," despite the fact that the exec is only in his late 40s.

Read the TheStreet coverage

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments